FDA approves generic Cymbalta for Dr Reddy
Dr Reddy's Laboratories has launched duloxetine delayed-release capsules USP 20 mg, 30 mg and 60 mg in the US market. According to IMS health, Cymbalta (duloxetine delayed-release capsules) brand and generic had US sales of $ 5.04 billion for the most recent 12 months ending April 2014. The US FDA in December last year approved the first generic versions of Cymbalta (duloxetine delayed-release capsules), for Aurobindo Pharma Ltd, Dr Reddy's Laboratories Ltd, Lupin Ltd, Sun Pharma Global FZE, Teva Pharmaceuticals USA and Torrent Pharmaceuticals Ltd to market the drug in various strengths.
The US Patent for Cymbalta expired in December 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.